Case study

Transform osteomyelitis in diabetic foot

Courtesy of Mr Jogia
Consultant Podiatric Surgeon, Leicester, UK

Clinical particulars

67-year-old male with type 2 diabetes and BMI of 37 presented with osteomyelitis and interphalangeal joint destruction to his left hallux. This failed to resolve with conservative treatment regime of oral antibiotics and off-loading. Surgical management was to amputate the left hallux, however there was a risk of re-ulceration as he was already receiving treatment for Charcot arthropathy to his right foot.


As a last effort to prevent amputation, surgical debridement was carried out, the bone was fenestrated and STIMULAN mixed with vancomycin and gentamicin used to fill the cavities. Surgery was carried out as a day case under local anaesthetic.


2 weeks post-operatively, the toe reduced in size. At the 16-month x-ray, STIMULAN was seen to be completely absorbed, the patient was infection-free and amputation had been avoided.


For indications, contraindications, warnings and precautions see Instructions for Use.  The treating physician is responsible for deciding the type and quantity of antibiotic used.  Concurrent use of locally administered antibiotics may affect setting time.

The mixing of antibiotics with the STIMULAN Kit / STIMULAN Rapid Cure device is considered off-label usage of the medicinal product. To do so is at the professional risk of the surgeon / healthcare professional.

This page may include the use of STIMULAN or techniques that go beyond the current clearance/ approval granted by the relevant regulatory authority. Please contact your local representative for further information.

©2018, Biocomposites, STIMULAN, Bringing Calcium to Life, Power to Transform Outcomes and DRy26 are trademarks/registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorised copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

Patents granted: GB2367552, EP 1204599 B1, US 6780391, EP 2594231 B1, US 8883063, CN ZL201210466117.X, GB2496710, EP 3058899 B1

Patents pending: GB1502655.2, US 15/040075, CN 201610089710.5, US 15/288328, GB1704688.9, EP 18275044.8, US 15/933936